Dana dhuwit perusahaan: ZyVersa (ZVSA)

ZyVersa Therapeutics - logo grafis emiten ZVSA

ZyVersa Therapeutics (ZVSA) invests in nanotechnology and inflammasome inhibitors to combat kidney diseases. The efficiency of these developments is enhanced through the automation of cellular assays. The company's cash position on this chart demonstrates financial stability, where the metric value stands at 0.00. This capital supports the active phase of clinical trials for drugs targeting metabolic disorders and inflammation.

Aset likuid perusahaan: ZyVersa Therapeutics (ZVSA) kanggo 28.04.2023 - 02.08.2025

Rincian metrik keuangan lan pasar ZyVersa Therapeutics, Inc. (ZVSA)

Ringkesan analisis perusahaan:ZyVersa Therapeutics
Sampel barang zyversa.com

This indicator reflects the absolute amount of liquid assets available for operational management. The metric measures financial stability, balancing the minimization of default risks with capital efficiency. For ZyVersa Therapeutics (ZVSA), this reserve is critical during the development of inflammasome platforms against nephropathies. Sufficient capital ensures autonomy in creating treatments for renal inflammation. By analyzing the current cash level, an investor assesses the company's survival horizon.